Nuclear Medicine

Maps glucose metabolism to help find and monitor cancers; also used in heart viability and certain brain conditions for functional assessment.

Targets PSMA to detect prostate cancer at staging and recurrence, delivering high‑contrast pelvic imaging.

A radioactive diagnostic agent indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment.

PSMA-targeted PET imaging agent for prostate cancer diagnosis, treatment response assessment, and recurrence detection.

Dedicated imaging agent for neuroendocrine tumors (NETs), assesses somatostatin receptor-positive tumors for diagnosis and PRRT treatment pairing.

Hepatocellular carcinoma (HCC) metabolic imaging and prostate cancer assessment, suitable for PET/CT lipid metabolism pathway detection.

Comprehensive OEM and ODM for radiopharmaceuticals: formulation, technology transfer, cGRPP documentation, QC release, compliant packaging, and distribution.

Advancing pipeline radiotracers for oncology and neurology, collaborative research, early access, quantification, guideline-aligned protocols.